中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(5): 855-861

Value of alpha-fetoprotein combined with prealbumin in evaluating the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.12449/JCH250510
  • 1.

    Department of Gastroenterology，The Affiliated Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

  • 2.

    Department of Gastroenterology，The General Hospital of Western Theater Command，Chengdu 610083，China

Research funding:

Project of Sichuan Provincial Administration of Traditional Chinese Medicine (2023MS458)

More Information
  • Corresponding author: TANG Shanhong， tangshanhong@swjtu.edu.cn （ORCID： 0000-0001-6652-2942）
  • Received Date: 2024-09-07
  • Accepted Date: 2024-11-11
  • Published Date: 2025-05-25
    Abstract
  •   Objective  To investigate the association of alpha-fetoprotein （AFP） and prealbumin （PAB） with the 90-day prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure （HBV-ACLF）， as well as the difference in 90-day prognosis between the patients with different levels of AFP and PAB.  Methods  A total of 371 HBV-ACLF patients who were hospitalized in The General Hospital of Western Theater Command from January 2018 to January 2023 were enrolled， and according to the follow-up results on day 90 after discharge， they were divided into survival group with 216 patients and death group with 155 patients. The medical record system was used to collect general data， AFP， PAB， and other related laboratory markers. The t-test was used for comparison of normally distributed continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for comparison between two groups. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups and further comparison between two groups. The chi-square test was used for comparison of categorical data between groups. The multivariate logistic regression analysis was used to identify the influencing factors for the prognosis of HBV-ACLF patients. The receiver operating characteristic （ROC） curve was plotted for AFP and PAB to determine their cut-off values. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison.  Results  Compared with the death group， the survival group had significantly higher levels of hemoglobin （Hb）， PAB， AFP， and platelet count （PLT） （all P<0.05） and significantly lower age， total bilirubin （TBil）， white blood cell count （WBC）， cystatin， creatinine， urea， international normalized ratio （INR）， Model for End-Stage Liver Disease （MELD） score， proportion of patients with Child-Pugh class C， and incidence rates of ascites and hepatic encephalopathy （all P<0.05）. The multivariate logistic regression analysis showed that PAB （odds ratio ［OR］=0.985， 95% confidence interval ［CI］： 0.972‍ ‍—‍ ‍0.998， P=0.024）， AFP （OR=0.998， 95%CI： 0.996‍ ‍—‍ ‍1.000， P=0.028）， PLT （OR=0.989， 95%CI： 0.982‍ ‍—‍ ‍0.996， P=0.003）， age （OR=1.046， 95%CI： 1.018‍ ‍—‍ ‍1.075， P=0.001）， TBil （OR=1.004， 95%CI： 1.002‍ ‍—‍ ‍1.006， P<0.001）， and WBC （OR=1.237， 95%CI： 1.110‍ ‍—‍ ‍1.379， P<0.001） were independent influencing factors for 90-day prognosis in HBV-ACLF patients. According to the cut-off values of AFP and PAB on ROC curves， the patients were divided into group A with 102 patients （AFP≥73.19 ng/mL and PAB≥22.55 mg/L）， group B with 170 patients （AFP≥73.19 ng/mL and PAB<22.55 mg/L； AFP<73.19 ng/mL and PAB≥22.55 mg/L）， and group C with 99 patients （AFP<73.19 ng/mL and PAB<22.55 mg/L）. There were significant differences between these three groups in age， Hb， INR， MELD score， and Child-Pugh class （all P<0.05）. The Kaplan-Meier survival analysis showed that group A had a significantly higher 90-day cumulative survival rate than groups B and C （χ2=19.825， P<0.001）.  Conclusion  AFP combined with PAB can better predict the 90-day prognosis of HBV-ACLF patients， and patients with high levels of AFP and PAB tend to have a lower mortality rate on day 90.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    LI X, ZHANG L, PU CM, et al. Liver transplantation in acute-on-chronic liver failure: Timing of transplantation and selection of patient population[J]. Front Med(Lausanne), 2022, 9: 1030336. DOI: 10.3389/fmed.2022.1030336.
    [2]
    MU XY, TONG JJ, XU X, et al. World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 3): 101548. DOI: 10.1016/j.clinre.2020.09.009.
    [3]
    SHI Y, YANG Y, HU YR, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults[J]. Hepatology, 2015, 62( 1): 232- 242. DOI: 10.1002/hep.27795.
    [4]
    WANG XP, SUN MY, YANG XJ, et al. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure[J]. Biomed Res Int, 2020, 2020: 5062873. DOI: 10.1155/2020/5062873.
    [5]
    LI CY, HU H, BAI CZ, et al. Alpha-fetoprotein and APRI as predictive markers for patients with Type C hepatitis B-related acute-on-chronic liver failure: A retrospective study[J]. BMC Gastroenterol, 2024, 24( 1): 191. DOI: 10.1186/s12876-024-03276-x.
    [6]
    WU H, LIU L, TANG SH. The value of liver regeneration ability in prognosis assessment of liver failure should be emphasized[J]. J Southwest Med Univ, 2024, 47( 1): 25- 28. DOI: 10.3969/j.issn.2096-3351.2024.01.006.

    吴红, 刘林, 汤善宏. 重视肝再生能力在肝衰竭预后评估中的价值[J]. 西南医科大学学报, 2024, 47( 1): 25- 28. DOI: 10.3969/j.issn.2096-3351.2024.01.006.
    [7]
    YIN Y, CHENG JW, CHEN FY, et al. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma[J]. Ann Transl Med, 2021, 9( 9): 774. DOI: 10.21037/atm-20-7842.
    [8]
    LI YC, LIU XC, JIANG Y, et al. Low preoperative prealbumin predicts the prevalence of complications following liver transplantation[J]. BMC Gastroenterol, 2021, 21( 1): 233. DOI: 10.1186/s12876-021-01818-1.
    [9]
    ZHANG H, YANG K, WANG Q, et al. Prealbumin as a predictor of short-term prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Infect Drug Resist, 2023, 16: 2611- 2623. DOI: 10.2147/IDR.S402585.
    [10]
    WANG XP, TANG SH, YANG DH, et al. Value of prealbumin changes in assessment of liver function in patients with acute-on-chronic liver failure[J]. Med J Natl Defending Forces Southwest China, 2019, 29( 7): 760- 762. DOI: 10.3969/j.issn.1004-0188.2019.07.013.

    王孝平, 汤善宏, 杨德会, 等. 前白蛋白变化对慢加急性肝衰竭肝功能评估的价值[J]. 西南国防医药, 2019, 29( 7): 760- 762. DOI: 10.3969/j.issn.1004-0188.2019.07.013.
    [11]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [12]
    YEO YH, LEE YT, TSENG HR, et al. Alpha-fetoprotein: Past, present, and future[J]. Hepatol Commun, 2024, 8( 5): e0422. DOI: 10.1097/HC9.0000000000000422.
    [13]
    SO J, KIM A, LEE SH, et al. Liver progenitor cell-driven liver regeneration[J]. Exp Mol Med, 2020, 52( 8): 1230- 1238. DOI: 10.1038/s12276-020-0483-0.
    [14]
    MICHALOPOULOS GK, BHUSHAN B. Liver regeneration: Biological and pathological mechanisms and implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 1): 40- 55. DOI: 10.1038/s41575-020-0342-4.
    [15]
    LI JN, HAN C, WANG XP, et al. Current research on liver regeneration: Pathogenesis and serum markers[J]. J Clin Hepatol, 2020, 36( 8): 1896- 1899. DOI: 10.3969/j.issn.1001-5256.2020.08.048.

    李嘉妮, 韩川, 王孝平, 等. 肝再生的发生机制及血清标志物的研究现状[J]. 临床肝胆病杂志, 2020, 36( 8): 1896- 1899. DOI: 10.3969/j.issn.1001-5256.2020.08.048.
    [16]
    WU H, LI H, TANG SH. Role of alpha-fetoprotein in prognostic evaluation of patients with liver failure[J]. J Clin Hepatol, 2021, 37( 11): 2706- 2709. DOI: 10.3969/j.issn.1001-5256.2021.11.048.

    吴红, 李浩, 汤善宏. 甲胎蛋白在肝衰竭患者预后判断中的作用[J]. 临床肝胆病杂志, 2021, 37( 11): 2706- 2709. DOI: 10.3969/j.issn.1001-5256.2021.11.048.
    [17]
    ZHAO Q, YANG JJ, ZHONG YP, et al. Value of alpha-fetoprotein on the diagnosis and treatment of hepatitis B virus infection-related acute-on-chronic liver failure[J/CD]. Chin J Liver Dis(Electronic Version), 2024, 16( 3): 32- 35. DOI: 10.3969/j.issn.1674-7380.2024.03.005.

    赵琴, 杨军杰, 钟炎平, 等. 甲胎蛋白在乙型肝炎病毒感染相关慢加急性肝衰竭诊治中的价值[J/CD]. 中国肝脏病杂志(电子版), 2024, 16( 3): 32- 35. DOI: 10.3969/j.issn.1674-7380.2024.03.005.
    [18]
    CHEN MJ, LI X, TANG SH. Research progress on multidimensional evaluation of liver function in the prognosis of patients with liver failure[J]. Clin J Med Offic, 2023, 51( 9): 901- 903, 907. DOI: 10.16680/j.1671-3826.2023.09.05.

    陈美娟, 李雪, 汤善宏. 多维度评估肝功能在肝衰竭患者预后中研究进展[J]. 临床军医杂志, 2023, 51( 9): 901- 903, 907. DOI: 10.16680/j.1671-3826.2023.09.05.
    [19]
    RANASINGHE RN, BISWAS M, VINCENT RP. Prealbumin: The clinical utility and analytical methodologies[J]. Ann Clin Biochem, 2022, 59( 1): 7- 14. DOI: 10.1177/0004563220931885.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1538) PDF downloads(57) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return